Bifogade filer
PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Arctic Bioscience has today released its Annual Report 2024, including the Board of Directors report and financial statements. The report and annual accounts were approved by the Board of Directors after close of business on 6th of May 2025.
On 27 February 2025 Arctic Bioscience reported preliminary and unaudited key results for the fourth quarter and full year 2024. Today's audited accounts include adjustments to gross profit and gross margin due to extraordinary cost provisions of NOK 2,34 million in relation to recall of goods sold to business partners in Q4 2024. The recall issue arose late Q1 2025 and is undergoing standard quality procedures.
- Gross profit is reduced from NOK 5,4 million to NOK 3,1 million in Q4 2024
- Gross margin is reduced from 34,4 % to 20 % in Q4 2024
- Gross profit is reduced from NOK 14,2 million to NOK 11,9 million for full year 2024
- Gross margin is reduced from 32,7 % to 27,1 % for full year 2024
The report is attached to this stock notice and is available on the company's website.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.